Literature DB >> 21844301

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.

Serena Spudich1, Magnus Gisslen, Lars Hagberg, Evelyn Lee, Teri Liegler, Bruce Brew, Dietmar Fuchs, Giuseppe Tambussi, Paola Cinque, Frederick M Hecht, Richard W Price.   

Abstract

BACKGROUND: Central nervous system (CNS) human immunodeficiency virus (HIV) infection and immune activation lead to brain injury and neurological impairment. Although HIV enters the nervous system soon after transmission, the magnitude of infection and immunoactivation within the CNS during primary HIV infection (PHI) has not been characterized.
METHODS: This cross-sectional study analyzed cerebrospinal fluid (CSF) and blood from 96 participants with PHI and compared them with samples from neuroasymptomatic participants with chronic infection and ≥ 200 or < 200 blood CD4 T cells/μL, and with samples from HIV-seronegative participants with respect to CSF and plasma HIV RNA, CSF to serum albumin ratio, and CSF white blood cell counts (WBC), neopterin levels, and concentrations of chemokines CXCL10 and CCL2.
RESULTS: The PHI participants (median 77 days post transmission) had CSF HIV RNA, WBC, neopterin, and CXCL10 concentrations similar to the chronic infection participants but uniquely high albumin ratios. 18 participants had ≤ 100 copies/mL CSF HIV RNA, which was associated with low CSF to plasma HIV ratios and levels of CSF inflammation lower than in other PHI participants but higher than in HIV-seronegative controls.
CONCLUSIONS: Prominent CNS infection and immune activation is evident during the first months after HIV transmission, though a proportion of PHI patients demonstrate relatively reduced CSF HIV RNA and inflammation during this early period.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21844301      PMCID: PMC3156103          DOI: 10.1093/infdis/jir387

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  49 in total

1.  Acute ataxia coincident with seroconversion for anti-HIV.

Authors:  E Scarpini; G Sacilotto; A Lazzarin; L Geremia; R Doronzo; G Scarlato
Journal:  J Neurol       Date:  1991-09       Impact factor: 4.849

2.  Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection.

Authors:  Paola Cinque; Arabella Bestetti; Roberta Marenzi; Serena Sala; Magnus Gisslen; Lars Hagberg; Richard W Price
Journal:  J Neuroimmunol       Date:  2005-08-08       Impact factor: 3.478

3.  Ataxic neuropathy associated with human immunodeficiency virus seroconversion.

Authors:  F Castellanos; J Mallada; C Ricart; J A Zabala
Journal:  Arch Neurol       Date:  1994-03

4.  Clinical and epidemiologic features of primary HIV infection.

Authors:  T Schacker; A C Collier; J Hughes; T Shea; L Corey
Journal:  Ann Intern Med       Date:  1996-08-15       Impact factor: 25.391

Review 5.  The neuropathogenesis of AIDS.

Authors:  Francisco González-Scarano; Julio Martín-García
Journal:  Nat Rev Immunol       Date:  2005-01       Impact factor: 53.106

6.  Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10.

Authors:  S A Kolb; B Sporer; F Lahrtz; U Koedel; H W Pfister; A Fontana
Journal:  J Neuroimmunol       Date:  1999-01-01       Impact factor: 3.478

7.  Cerebrospinal fluid neopterin concentrations in central nervous system infection.

Authors:  L Hagberg; L Dotevall; G Norkrans; M Larsson; H Wachter; D Fuchs
Journal:  J Infect Dis       Date:  1993-11       Impact factor: 5.226

8.  Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease.

Authors:  D E Griffin; J C McArthur; D R Cornblath
Journal:  Neurology       Date:  1991-01       Impact factor: 9.910

9.  Early viral brain invasion in iatrogenic human immunodeficiency virus infection.

Authors:  L E Davis; B L Hjelle; V E Miller; D L Palmer; A L Llewellyn; T L Merlin; S A Young; R G Mills; W Wachsman; C A Wiley
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

10.  Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.

Authors:  Serena S Spudich; Annelie C Nilsson; Nicole D Lollo; Teri J Liegler; Christos J Petropoulos; Steven G Deeks; Ellen E Paxinos; Richard W Price
Journal:  BMC Infect Dis       Date:  2005-11-02       Impact factor: 3.090

View more
  87 in total

1.  HIV gp120 sequence variability associated with HAND in Hispanic Women.

Authors:  Krystal Colón; Fabián Vázquez-Santiago; Vanessa Rivera-Amill; Gisela Delgado; Steven E Massey; Valerie Wojna; Richard J Noel; Loyda M Meléndez
Journal:  J Virol Antivir Res       Date:  2015-10-06

2.  The role of catecholamines in HIV neuropathogenesis.

Authors:  R Nolan; P J Gaskill
Journal:  Brain Res       Date:  2018-04-27       Impact factor: 3.252

3.  Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?

Authors:  Peter D Burbelo; Richard W Price; Lars Hagberg; Hiroyu Hatano; Serena Spudich; Steven G Deeks; Magnus Gisslén
Journal:  J Infect Dis       Date:  2018-03-13       Impact factor: 5.226

4.  Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.

Authors:  Michael J Peluso; Serena Spudich
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

5.  Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.

Authors:  Viktor Dahl; Julia Peterson; Dietmar Fuchs; Magnus Gisslen; Sarah Palmer; Richard W Price
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

6.  Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection.

Authors:  Andrew C Young; Constantin T Yiannoutsos; Manu Hegde; Evelyn Lee; Julia Peterson; Rudy Walter; Richard W Price; Dieter J Meyerhoff; Serena Spudich
Journal:  Neurology       Date:  2014-09-26       Impact factor: 9.910

7.  CROI 2015: Neurologic Complications of HIV Infection.

Authors:  Serena S Spudich; Beau M Ances
Journal:  Top Antivir Med       Date:  2015 Mar-Apr

Review 8.  Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS.

Authors:  Maria M Bednar; Christa Buckheit Sturdevant; Lauren A Tompkins; Kathryn Twigg Arrildt; Elena Dukhovlinova; Laura P Kincer; Ronald Swanstrom
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

9.  Neuropsychological test performance before and after HIV-1 seroconversion: the Multicenter AIDS Cohort Study.

Authors:  Quynh T Vo; Christopher Cox; Xiuhong Li; Lisa P Jacobson; Rosemary McKaig; Ned Sacktor; Ola A Selnes; Eileen Martin; James T Becker; Eric N Miller
Journal:  J Neurovirol       Date:  2012-12-11       Impact factor: 2.643

Review 10.  Where does HIV hide? A focus on the central nervous system.

Authors:  Melissa Churchill; Avindra Nath
Journal:  Curr Opin HIV AIDS       Date:  2013-05       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.